Immunome Insider Sells Shares Ahead of FDA Milestone

Isaac Barchas, director at Immunome (NASDAQ:IMNM), sold 100,000 shares indirectly through a Rule 10b5-1 trading plan. The sale occurred as the stock had surged by 181% over one year and ahead of an anticipated FDA milestone.

By Jonathan Ponciano, The Motley Fool Mon, July 13, 2026 at 12:04 AM GMT+3 4 min read · Yahoo Finance · July 12, 2026, 21:04 UTC

Immunome Insider Sells Shares Ahead of FDA Milestone

Tickers: $IMNM

Topics: biotech FDA SEC filing stock sale

Read the full article at Yahoo Finance

More World news

Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC
AIRO Group Holdings Reaffirms 2026 Revenue Growth Guidance Amid $200 Million Drone Backlog Seeking Alpha · November 12, 2026, 18:40 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy TechCrunch · November 12, 2026, 18:39 UTC
Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy Seeking Alpha · November 12, 2026, 18:35 UTC
EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC